Graham Capital Management, L.P. Biocryst Pharmaceuticals Inc Transaction History

Graham Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $136,103 - $185,024	27,330 Added 72.83%	64,856 $388,000
Q3 2023 Nov 22, 2023	SELL	$6.71 - $7.92 $744 - $879	-111 Reduced 0.29%	37,526 $265,000
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $261,953 - $331,581	37,637 New	37,637 $264,000
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $1.49 Million - $2.04 Million	-137,741 Reduced 84.65%	24,972 $314,000
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $1.28 Million - $2.91 Million	162,713 New	162,713 $1.72 Million

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.